CDK4/6 inhibitors have also been explored in the treatment of lung cancer, but the efficacy of single agent therapy has been found to be limited , with an ORR between 0%–8%, which is not high enough to instigate the wide use of a single CDK4/6 inhibitor in clinical practice.19, 20, 21. The gene discussed is CDK4; the disease is lung carcinoma.